Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2022 / N 1

Комплексная терапия когнитивных нарушений при цереброваскулярных заболеваниях
Н.В. Пизова, Н.А. Пизов, А.В. Пизов

References

1. Truelsen T, Piechowski-Jóźwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke incidence and prevalence in Europe: a review of available data. European Journal of Neurology 2006 Jun;13(6):581-98.
2. Pucciarelli G, Ausili D, Galbussera AA, Rebora P, Savini S, Simeone S, Alvaro R, Vellone E. Quality of life, anxiety, depression and burden among stroke caregivers: a longitudinal, observational multicentre study. Journal of Advanced Nursing 2018;74:1875-87.
3. Klochikhina OA, Stakhovskaya LV. Comparative analysis of epidemiological indices of stroke based on the data of a regional population register from 2009 to 2012. Neuronews 2015;2(5):1-6 (In Russian).
4. Caprio FZ, Sorond FA. Cerebrovascular disease: primary and secondary stroke prevention. The Medical Clinics of North America 2019 Mar;103(2):295-308.
5. Khaku AS, Tadi P. Cerebrovascular disease [Internet]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022-. Last update 2021 Sep 29.
6. Jongsiriyanyong S, Limpawattana P. Mild cognitive impairment in clinical practice: a review article. American Journal of Alzheimer’s Disease & Other Dementias 2018 Dec;33(8):500-7.
7. Han JS, Kim YH. Neck circumference and incidence of cerebrovascular disease over 12 years among Korean adults. Osong Public Health and Research Perspectives 2022 Feb;13(1):71-9.
8. Marrugat J, Arboix A, García-Eroles L, Salas T, Vila J, Castell C, Tresserras R, Elosua R. The estimated incidence and case fatality rate of ischemic and hemorrhagic cerebrovascular disease in 2002 in Catalonia. Revista Española de Cardiología 2007 Jun;60(6):573-80.
9. Lau WL, Huisa BN, Fisher M. The cerebrovascular-chronic kidney disease connection: perspectives and mechanisms. Translational Stroke Research 2017 Feb;8(1):67-76.
10. Graff-Radford J. Vascular cognitive impairment. Continuum (Minneapolis, Minn.) 2019 Feb;25(1):147-64.
11. Cherdak MA, Parfenov VA. Cognitive disorders in patients with ischemic stroke: a review. Neurological Journal 2011;16(6):37-44 (In Russian).
12. Palmer K, Wang HX, Bäckman L, Winblad B, Fratiglioni L. Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. The American Journal of Psychiatry 2002 Mar;159(3):436-42.
13. Pisova NV. Outpatient management of patients after severe stroke with dementia. Neurology, Neuropsychiatry, Psychosomatics 2013;4:78-84 (In Russian).
14. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Estep K, Abate LH, Akinyemiju RF, Ali R, Alvis-Guzman N, Azzopardi P, Banerjee A, Bärnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, Catalá-López F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, Hanke GJ, Jonas JB, Judd SE, Khang YH, Khosravi A, Kim YJ, Kimokoti RW, Kokubo Y, Kolte D, Lopez A, Lotufo PA, Malekzadeh R, Melaku YA, Mensah GA, Misganaw A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN, Ohkubo T, Pourmalek F, Rafay A, Rai RK, Rojas-Rueda D, Sampson UK, Santos IS, Sawhney M, Echutte AE, Sepanlou SG, Shifa GT, Shiue I, Tedla BA, Thrift AG, Tonelli M, Truelsen T, Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari T, Venketasubramanian N, Vlasso VV, Vos T, Westerman R, Yan LL, Yano Y, Yonemoto N, El Sayed Zaki M, Murray CJL. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017 Jan;317(2):165-82.
15. Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer’s disease. The Lancet 2016 Jul;388(10043):505-17.
16. Iadecola C, Gottesman RF. Neurovascular and cognitive dysfunction in hypertension. Circulation Research 2019 Mar;124(7):1025-44.
17. Elias MF, Wolf PA, D’Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham study. American Journal of Epidemiology 1993 Sep;138(6):353-64.
18. Ruitenberg A, Skoog I, Ott A, Aevarsson O, Lernfelt B, van Harskamp F, Hofman A, Breteler MM. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 study. Dementia and Geriatric Cognitive Disorders 2001 Jan-Feb;12(1):33-9.
19. McGrath ER, Beiser AS, DeCarli C, Plourde KL, Vasan RS, Greenberg SM, Seshadri S. Blood pressure from mid- to late life and risk of incident dementia. Neurology 2017 Dec;89(24):2447-54.
20. Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker L, Coresh J, Knopman D, Power MC, Rawlings A, Sharrett AR, Wruck LM, Mosley TH. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA. Neurology 2014 Oct;71(10):1218-27.
21. Goldstein FC, Hajjar IM, Dunn CB, Levey AI, Wharton W. The relationship between cognitive functioning and the JNC-8 guidelines for hypertension in older adults. The Journals of Gerontology. Series A. Biological Sciences and Medical Sciences 2017 Jan;72(1):121-6.
22. Sikaroodi H, Yadegari S, Miri SR. Cognitive impairments in patients with cerebrovascular risk factors: a comparison of Mini Mental Status Exam and Montreal Cognitive Assessment. Clinical Neurology and Neurosurgery 2013 Aug;115(8):1276-80.
23. van Veluw SJ, Shih AY, Smith EE, Chen C, Schneider JA, Wardlaw JM, Greenberg SM, Biessels GJ. Detection, risk factors, and functional consequences of cerebral microinfarcts. The Lancet. Neurology 2017 Sep;16(9):730-40.
24. Biesbroek JM, Weaver NA, Biessels GJ. Lesion location and cognitive impact of cerebral small vessel disease. Clinical Sciences 2017 Apr;131(8):715-28.
25. Akoudad S, Wolters FJ, Viswanathan A, de Bruijn RF, van der Lugt A, Hofman A, Koudstaal PJ, Ikram A, Vernooij MW. Association of cerebral microbleeds with cognitive decline and dementia. JAMA. Neurology 2016 Aug;73(8):934-43.
26. Brown R, Benveniste H, Black SE, Charpak S, Dichgans M, Joutel A, Nedergaard M, Smith KJ, Zlokovic BV, Wardlaw JM. Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovascular Research 2018 Sep;114(11):1462-73.
27. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM. Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. Stroke 2008 Feb;39(2):349-54.
28. Seo SW, Lee JM, Im K, Park JS, Kim SH, Kim ST, Ahn HJ, Chin J, Cheong HK, Weiner MW, Na DL. Cortical thinning related to periventricular and deep white matter hyperintensities. Neurobiology of Aging 2012 Jul;33(7):1156-67.
29. Rosenberg GA. Extracellular matrix inflammation in vascular cognitive impairment and dementia. Clinical Sciences (London, England: 1979) 2017 Mar;131(6):425-37.
30. Guo S, Kim WJ, Lok J, Lee SR, Besancon E, Luo BH, Stins MF, Wang X, Dedhar S, Lo EH. Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proceedings of the National Academy of Sciences of the USA 2008 May;105(21):7582-7.
31. Iadecola C. The pathobiology of vascular dementia. Neuron 2013 Nov;80(4):844-66.
32. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, Day JD. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Heart Rhythm 2010 Apr;7(4):433-7.
33. de Bruijn RF, Heeringa J, Wolters FJ, Franco OH, Stricker BHC, Hofman A, Koudstaal PJ, Ikram MA. Association between atrial fibrillation and dementia in the general population. JAMA. Neurology 2015 Nov;72(11):1288-94.
34. Singh-Manoux A, Fayosse A, Sabia S, Canonico M, Bobak M, Elbaz A, Kivimäki M, Dugravot A. Atrial fibrillation as a risk factor for cognitive decline and dementia. European Heart Journal 2017 Sep;38(34):612-8.
35. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Annals of Internal Medicine 2013 Mar;158(5 Pt 1):338-46.
36. Bernhardt P, Schmidt H, Hammerstingl C, Luderitz B, Omran H. Patients at high risk with atrial fibrillation: a prospective and serial follow-up during 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. Journal of the American Society of Echocardiography 2005 Sep;18(9):919-24.
37. Gaita F, Corsinovi L, Anselmino M, Raimondo C, Pianelli M, Toso E, Bergamasco L, Boffano C, Valentini MC, Cesarani F, Scaglione M. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. Journal of the American College of Cardiology 2013;62(21):1990-7.
38. Wang Z, van Veluw SJ, Wong A, Liu W, Shi L, Jie Yang J, Xiong Y, Lau A, Biessels GJ, Mok VCT. Risk factors and cognitive relevance of cortical cerebral microinfarcts in patients with ischemic stroke or transient ischemic attack. Stroke 2016 Oct;47(10):2450-5.
39. Wyse DG. Therapeutic considerations in applying rate control therapy for atrial fibrillation. Journal of Cardiovascular Pharmacology 2008 Jul;52(1):11-7.
40. Lavy S, Stern S, Melamed E, Cooper G, Keren A, Levy P. Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke 1980 Jan-Feb;11(1):35-8.
41. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nature Reviews. Endocrinology 2018 Oct;14(10):591-604.
42. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. The Lancet. Neurology 2006 Jan;5(1):64-74.
43. Koekkoek PS, Kappelle LJ, van den Berg E, Rutten GE, Biessels GJ. Cognitive function in patients with diabetes mellitus: guidance for daily care. The Lancet. Neurology 2015 Mar;14(3):329-40.
44. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. Journal of Diabetes Investigation 2013 Nov;4(6):640-50.
45. Zhang J, Chen C, Hua S, Liao H, Wang M, Xiong Y, Cao F. An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer’s disease. Diabetes Research and Clinical Practice 2017 Feb;124:41-7.
46. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 2005 Mar;28(3):726-35.
47. Ho MS, Weller NJ, Ives FJ, Carne CL, Murray K, Vanden Driesen RI, Nguyen TP, Robins PD, Bulsara M, Davis EA, Jones TW. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. The Journal of Pediatrics 2008 Sep;153(3):385-90.
48. Monette MC, Baird A, Jackson DL. A meta-analysis of cognitive functioning in nondemented adults with type 2 diabetes mellitus. Canadian Journal of Diabetes 2014 Dec;38(6):401-8.
49. Palta P, Schneider AL, Biessels GJ, Touradji P, Hill-Briggs F. Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. Journal of the International Neuropsychological Society 2014 Mar;20(3):278-91.
50. Brady CC, Vannest JJ, Dolan LM, Kadis DS, Lee GR, Holland SK, Khoury JC, Shah AS. Obese adolescents with type 2 diabetes perform worse than controls on cognitive and behavioral assessments. Pediatric Diabetes 2017 Jun;18(4):297-303.
51. Yates KF, Sweat V, Yau PL, Turchiano MM, Convit A. Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 Sep;32(9):2060-7.
52. van den Berg E, de Craen AJ, Biessels GJ, Gussekloo J, Westendorp RG. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia 2006 Sep;49(9):2015-23.
53. Strachan MWJ, Reynolds RM, Frier BM, Mitchell RJ, Price JF. The relationship between type 2 diabetes and dementia. British Medical Bulletin 2008;88(1):131-46.
54. Fontbonne A, Berr С, Ducimetière P, Alpérovitch A. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care 2001 Feb;24(2):366-70.
55. Messier C. Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiology of Aging 2005 Dec;26(Suppl 1):26-30.
56. Feinkohl I, Price JF, Strachan MW, Frier BM. The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors. Alzheimer’s Research & Therapy 2015 Jun 10;7(1):46.
57. Cai XJ, Xu HQ, Lu Y. C-peptide and diabetic encephalopathy. Chinese Medical Sciences Journal 2011 Jun;26(2):119-25.
58. Chuyko MR, Bodykhov MK, Skvortsova VI. Characteristics and features of the course of encephalopathy in insulin-dependent diabetes mellitus. SS Korsakov Journal of Neurology and Psychiatry 2010;110(5):4-8 (In Russian).
59. Patiño-Fernández AM, Delamater AM, Applegate EB, Brady E, Eidson M, Nemery R, Gonzalez-Mendoza L, Richton S. Neurocognitive functioning in preschool-age children with type 1 diabetes mellitus. Pediatric Diabetes 2010 Sep;11(6):424-30.
60. Biessels GJ, Luchsinger JA. Pathobiology of diabetic encephalopathy in animal models. In: Diabetes and the brain. Biessels GJ, Luchsinger JA, editors. Totowa, NY: Humana Press; 2010: 409-31.
61. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. The Lancet. Diabetes & Endocrinology 2014 Mar;2(3):246-55.
62. Haroon NN, Austin PC, Shah BR, Wu J, Gill SS, Booth GL. Risk of dementia in seniors with newly diagnosed diabetes: a population-based study. Diabetes Care 2015 Oct;38(10):1868-75.
63. Exalto LG, Biessels GJ, Karter AJ, Huang ES, Katon WJ, Minkoff JR, Whitmer RA. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. The Lancet. Diabetes & Endocrinology 2013 Nov;1(3):183-90.
64. Berman SE, Wang X, Mitchell CC, Kundu B, Jackson DC, Wilbrand SM, Varghese T, Hermann BP, Rowley HA, Johnson SC, Dempsey RJ. The relationship between carotid artery plaque stability and white matter ischemic injury. NeuroImage: Clinical 2015 Aug;9:216-22.
65. Wang A, Liu X, Chen G, Hao H, Wang Y, Wan Y. Association between carotid plaque and cognitive impairment in Chinese stroke population: the SOS-Stroke study. Scientific Reports 2017 Jun;7(1):3066.
66. Wang X, Mitchell CC, Varghese T, Jackson DC, Rocque BG, Hermann BP, Dempsey RJ. Improved correlation of strain indices with cognitive dysfunction with inclusion of adventitial layer with carotid plaque. Ultrasonic Imaging 2016 May;38(3):194-208.
67. Wang X, Jackson DC, Mitchell CC, Varghese T, Hermann BP, Kliewer MA, Kliewer MA, Dempsey RJ. Estimation of ultrasound strain indices in carotid plaque and correlation to cognitive dysfunction. Annual International Conference of the IEEE in the Engineering Medicine and Biology Society 2014;2014:5627-30.
68. Rocque BG, Jackson D, Varghese T, Hermann B, McCormick M, Kliewer M, Mitchell C, Dempsey RJ. Impaired cognitive function in patients with atherosclerotic carotid stenosis and correlation with ultrasound strain measurements. Journal of the Neurological Sciences 2012 Nov;322(1-2):20-4.
69. Jing X, Tao Z, Qing-Wu Y, Juan L, Yong C, Ming C. Carotid intima–media thickness and cognitive function in a middle-aged and older adult community: a cross-sectional study. Journal of Clinical Neuroscience 2013;20:1571-5.
70. Sander K, Bickel H, Förstl H, Etgen T, Briesenick C, Poppert H, Sander D. Carotid-intima media thickness is independently associated with cognitive decline. The INVADE study. International Journal of Geriatric Psychiatry 2010 Apr;25(4):389-94.
71. van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Annals of Neurology 2007 May;61(5):403-10.
72. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, Ives D, Dekosky ST, Kuller LH. Dementia and Alzheimer’s disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. Journal of the American Geriatrics Society 2005 Jul;53(7):1101-7.
73. Rossetti HC, Weiner M, Hynan LS, Cullum CM, Khera A, Lacritz LH. Subclinical atherosclerosis and subsequent cognitive function. Atherosclerosis 2015 Jul;241(1):36-41.
74. Brickman AM, Siedlecki KL, Muraskin J, Manly JJ, Luchsinger JA, Yeung LK, Brown TR, DeCarli C, Stern Y. White matter hyperintensities and cognition: testing the reserve hypothesis. Neurobiology of Aging 2011 Sep;32(9):1588-98.
75. Martinić-Popović I, Lovrencić-Huzjan A, Demarin V. Assessment of subtle cognitive impairment in stroke-free patients with carotid disease. Acta Clinica Croatica 2009 Sep;48(3):231-40.
76. Popovic IM, Lovrencic-Huzjan A, Simundic AM, Popovic A, Seric V, Demarin V. Cognitive performance in asymptomatic patients with advanced carotid disease. Cognitive and Behavioral Neurology 2011 Sep;24(3):145-51.
77. Romero JR, Beiser A, Seshadri S, Benjamin EJ, Polak JF, Vasan RS, Au R, DeCarli C, Wolf PA. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke 2009 May;40(5):1590-6.
78. Lal BK, Dux MC, Sikdar S, Goldstein C, Khan AA, Yokemick J, Zhao L. Asymptomatic carotid stenosis is associated with cognitive impairment. Journal of Vascular Surgery 2017 Oct;66(4):1083-92.
79. Balestrini S, Perozzi C, Altamura C, Vernieri F, Luzzi S, Bartolini M, Provinciali L, Silvestrini M. Severe carotid stenosis and impaired cerebral hemodynamics can influence cognitive deterioration. Neurology 2013 Jun;80(23):2145-50.
80. Yew B, Nation DA. Alzheimer’s Disease Neuroimaging Initiative. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia. Brain 2017 Jul;140(7):1987-2001.
81. Kandiah N, Goh O, Mak E, Marmin M, Ng A. Carotid stenosis: a risk factor for cerebral white-matter disease. Journal of Stroke and Cerebrovascular Disease 2014 Jan;23(1):136-9.
82. Birdsill AC, Koscik RL, Jonaitis EM, Johnson SC, Okonkwo OC, Hermann BP, Larue A, Sager MA, Bendlin BB. Regional white matter hyperintensities: aging, Alzheimer’s disease risk, and cognitive function. Neurobiology of Aging 2014 Apr;35(4):769-76.
83. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. The Lancet. Neurology 2012 Mar;11(3):272-82.
84. Chen WH, Jin W, Lyu PY, Liu Y, Li R, Hu M, Xiao XJ. Carotid atherosclerosis and cognitive impairment in nonstroke patients. Chinese Medical Journal 2017 Oct;130(19):2375-9.
85. Bugnicourt JM, Godefroy O, Chillon JM, Choukroun G, Massy ZA. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. Journal of the American Society of Nephrology 2013 Feb;24(3):353-63.
86. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Advances in Chronic Kidney Disease 2008 Apr;15(2):123-32.
87. Fazekas G, Fazekas F, Schmidt R, Kapeller P, Offenbacher H, Krejs GJ. Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. Journal of the Neurological Sciences 1995 Dec;134(1-2):83-8.
88. Chen YC, Su YC, Lee CC, Huang YS, Hwang SJ. Chronic kidney disease itself is a causal risk factor for stroke beyond traditional cardiovascular risk factors: a nationwide cohort study in Taiwan. PLoS One 2012;7(4):e36332.
89. Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 2006 Jul;67(2):224-8.
90. Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. The Lancet. Neurology 2014 Aug;13(8):823-33.
91. Naganuma T, Takemoto Y. New aspects of cerebrovascular diseases in dialysis patients. Contributions in Nephrology 2015;185:138-46.
92. Weiner DE, Bartolomei K, Scott T, Price LL, Griffith JL, Rosenberg I, Levey AS, Folstein MF, Sarnak MJ. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. American Journal of Kidney Diseases 2009 Mar;53(3):438-47.
93. Khatri M, Wright CB, Nickolas TL, Yoshita M, Paik MC, Kranwinkel G, Sacco RL, DeCarli C. Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke 2007 Dec;38(12):3121-6.
94. Eldehni MT, McIntyre CW. Are there neurological consequences of recurrent intradialytic hypotension? Seminars in Dialysis 2012 May;25(3):253-6.
95. Prohovnik I, Post J, Uribarri J, Lee H, Sandu O, Langhoff E. Cerebrovascular effects of hemodialysis in chronic kidney disease. Journal of Cerebral Blood Flow & Metabolism 2007 Nov;27(11):1861-9.
96. Sarnak MJ, Tighiouart H, Scott TM, Lou KV, Sorensen EP, Giang LM, Drew DA, Shaffi K, Strom JA, Singh AK, Weiner DE. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology 2013 Jan;80(5):471-80.
97. Murray AM, Tupper DE, Knopman DS, Gilbertson DT, Pederson SL, Li S, Smith GE, Hochhalter AK, Collins AJ, Kane RL. Cognitive impairment in hemodialysis patients is common. Neurology 2006 Jul;67(2):216-23.
98. Weiner DE, Scott TM, Giang LM, Agganis BT, Sorensen EP, Tighiouart H, Sarnak MJ. Cardiovascular disease and cognitive function in maintenance hemodialysis patients. American Journal of Kidney Diseases 2011 Nov;58(5):773-81.
99. Gan EH, Pearce SH. Clinical review: the thyroid in mind: cognitive function and low thyrotropin in older people. The Journal of Clinical Endocrinology & Metabolism 2012 Oct;97(10):3438-49.
100. Yao K, Zhao T, Zeng L, Yang J, Liu Y, He Q, Zou X. Non-invasive markers of cardiovascular risk in patients with subclinical hypothyroidism: a systematic review and meta-analysis of 27 case control studies. Scientific Reports 2018 Mar;8(1):4579.
101. Nomoto S, Kinno R, Ochiai H, Kubota S, Mori Y, Futamura A, Sugimoto A, Kuroda T, Yano S, Murakami H, Shirasawa T, Yoshimoto T, Minoura A, Kokaze A, Ono K. The relationship between thyroid function and cerebral blood flow in mild cognitive impairment and Alzheimer’s disease. PLoS One 2019 Apr;14(4):e0214676.
102. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. The Lancet. Neurology 2019 Jul;18(7):684-96.
103. Riba-Llena I, Jiménez-Balado J, Castañé X, Girona A, López-Rueda A, Mundet X, Jarca CI, Álvarez-Sabin J, Montaner J, Delgado P. Arterial stiffness is associated with basal ganglia enlarged perivascular spaces and cerebral small vessel disease load. Stroke 2018 May;49(5):1279-81.
104. Smith JW, Evans AT, Costall B, Smythe JW. Thyroid hormones, brain function and cognition: a brief review. Neuroscience & Biobehavioral Reviews 2002 Jan;26(1):45-60.
105. Abend WK, Tyler HR. Thyroid disease and the nervous system. In: Neurology and general medicine. The neurological aspects of medical disorders. 2nd ed. Aminoff MJ, editor. Chapter 18. New York, NY: Churchill Livingstone; 1995: 333-47.
106. Damulin IV, Orazmuradov GO. Neurological disorders in hypothyroidism. SS Korsakov Journal of Neurology and Psychiatry 2011;111(3):82-6 (In Russian).
107. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975 Nov;12(3):189-98.
108. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 2005 Apr;53(4):695-9.
109. Sun MK. Potential therapeutics for vascular cognitive impairment and dementia. Current Neuropharmacology 2018;16(7):1036-44.
110. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomized controlled trials. The Lancet. Neurology 2007 Sep;6(9):782-92.
111. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. Memantine for dementia. The Cochrane Database of Systematic Reviews 2019 Mar;3(3):CD003154.
112. Kosarev VV, Babanov SA. Clinical and pharmacological approaches to the use of nootropics in neurological diseases. Effective Pharmacotherapy 2010;16:16-21 (In Russian).
113. Onaolapo AY, Obelawo AY, Onaolapo OJ. Brain ageing, cognition and diet: a review of the emerging roles of food-based nootropics in mitigating age-related memory decline. Current Aging Science 2019;12(1):2-14.
114. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Research. Brain Research Review 1994 May;19(2):180-222.
115. Noble S, Benfield P. Piracetam: a review of its clinical potential in the management of patients with stroke. CNS Drugs 1998;9:497-511.
116. Giovannini MG, Rodinò P, Mutolo D, Pepeu G. Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo. Drug Development Research 1993 Apr;28(4):503-9.
117. Evans TL. Cognitive enhancers: new sight on the old problem. Annual Review in Pharmacology and Pharmacotherapy 2012;5:34-50.
118. Denderfield AP, Lewis K, Ho TY. GABA-mediated vasoconstriction and vasodilatation in physiological and pathological conditions. Neurotransmitters and neuropeptides in regulation of cardiovascular system. Los Angeles: UCP Press; 2009: 189-213.
119. Picamilon. Available from: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=&lf=&TradeNmR=%d0%9f%d0%b8%d0%ba%d0%b0%d0%bc%d0%b8%d0%bb%d0%be%d0%bd&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0®type=1%2c6&pageSize=10&order=RegDate&orderType=desc&pageNum=1 Accessed 2022 Apr 15 (In Russian).
120. Gusev YeI, Skvortsova VI. Neuroprotective therapy of ischemic stroke. Nervous Diseases 2002;1:3-7 (In Russian).
121. Picamilon is a metabolic cerebrovasculant and nootropic. Application in medical practice. Moscow: Akrikhin; 2002. 48 p. (In Russian).
122. Chugunov AV, Kabanov AA, Kazakov AYu. Complex therapy of a patient with chronic cerebral ischemia. Nervous Diseases 2021:3:25-31 (In Russian).
123. Kovalev GI, Vasilyeva EV, Salimov RM. The action of picamilon on prefrontal-cortex GABA receptors and behavior of C57BL/6 and BALB/C mice in closed cross-maze labyrinth. Russian Journal of Experimental and Clinical Pharmacology 2017;80(3):3-9 (In Russian).
124. Silkina IV, Ganshina TS, Seredenin SB, Mirzoyan RS. GABAergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon. Russian Journal of Experimental and Clinical Pharmacology 2005;68(1):20-4 (In Russian).
125. Ganshina TS, Kurdyumov IN, Kurza EV, Avdyunina NI, Pyatin BM, Maslennikov DV, Turilova AI, Mirzoyan RS. Cerebrovascular effects of picamilon and succinic acid esters 5-hydroxyadamintan-2-one in hemorrhagic and ischemic brain disorders. Russian Journal of Experimental and Clinical Pharmacology 2020;83(1):3-6 (In Russian).
126. Ganshina TS, Maslennikov DV, Kurdyumov IN, Kurza EV, Gnezdilova AV, Turilova AI, Mirzoyan RS. Picamilon efficiency in combined vascular pathology of brain and heart. Russian Journal of Experimental and Clinical Pharmacology 2022;85(1):3-6 (In Russian).
127. Yershov IN, Luchkina EV, Pokrovskiy MV, Pokrovskaya TG. The research of endothelio- and cardioprotective effects of lamotrigine, picamilon and valproates in experimental endothelial dysfunction. Kuban Scientific Medical Bulletin 2009;3(108):50-3 (In Russian).
128. Sigitova EV. Nicotinoyl gamma-aminobutyric acid in treatment of patients with diabetic encephalopathy. In: Neuroendocrine pathology. Issues of human reproduction. Materials of the International Scientific and Practical Conference of Students and Young Scientists. Balyazin VA, Yefremov VV, Dmitriyev MN, editors. Rostov-na-Donu: RosSMU; 2018: 35-44 (In Russian).
129. Laskov VB, Povetkin SV, Chernyshkov EV. Influence of cavinton forte and picamilon on cognitive disorders in patients with dyscirculatory encephalopathy. Clinical Gerontology 2009;15(10-11):17-21 (In Russian).
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]